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The EGF receptor is a widely expressed growth factor receptor that mediates the proliferative effects of EGF and other
members of the EGF ligand family. The receptor is composed of
an extracellular ligand-binding domain, an intracellular tyrosine kinase domain, and an ⬃230-amino acid-long C-terminal
tail (1) that is central to the signaling capabilities of the receptor
(2).
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Binding of EGF to the extracellular domain induces dimerization of the receptor (3, 4), leading to activation of the tyrosine
kinase domain (5). The receptor then undergoes autophosphorylation through which multiple tyrosines on the C-terminal tail become phosphorylated (6 – 8). These tyrosines
serve as sites for the binding of SH2 and PTB2 domain-containing proteins that mediate the downstream effects of the
growth factor (9).
The C-terminal tail of the EGF receptor contains a total of
nine tyrosine residues. Of these, seven have routinely been
reported to be phosphorylated (10 –15). These are Tyr-974,
Tyr-992, Tyr-1045, Tyr-1068, Tyr-1086, Tyr-1148, and Tyr1173. Of the remaining two, Tyr-1114 has occasionally been
identified as being phosphorylated in proteomics analyses (13).
Tyr-1101 has never been shown to become phosphorylated in
response to EGF but does appear to be phosphorylated by
pp60Src (16).
Although Tyr-1173 was initially thought to be the major site
of EGF receptor phosphorylation (17), more recent studies have
shown that Tyr-1148 is phosphorylated at a level up to five
times higher than that of Tyr-1173 (10). Tyr-1148 also appears
to be phosphorylated more rapidly than all but Tyr-1173 (14).
As a result, phosphorylation of Tyr-1148 has become a standard
marker for activation of the EGF receptor signaling pathways.
Tyr-1148 lies within a consensus sequence for the binding of
the PTB domain of the Shc adaptor protein (18). Grb2, which
binds to phospho-Shc, could thus be recruited to receptors containing this tyrosine, drawing in its cargo proteins such as SOS
and Gab1. The question arises as to whether Tyr-1148 is necessary and sufficient to support the activation of the panoply of
signaling pathways that lie downstream of the EGF receptor.
To address this question, we generated a series of EGF receptors, the single-Tyr EGF receptors, that contained only one of the
nine tyrosines in their C-terminal tail. The other eight tyrosines
were mutated to phenylalanine. Functional analyses of these
receptors demonstrated that the presence of any single tyrosine, except Tyr-1045, yielded a receptor that was signalingcompetent. Unexpectedly, the receptor with only Tyr-992
was found to be more broadly capable of signaling than any
of the other single-Tyr receptors, including the one containing only Tyr-1148. The signaling capacity of these single-Tyr
2

The abbreviations used are: PTB, phosphotyrosine-binding; RIPA, radioimmune precipitation assay; PH, pleckstrin homology.
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The EGF receptor is a classic receptor tyrosine kinase. It contains nine tyrosines in its C-terminal tail, many of which are
phosphorylated and bind proteins containing SH2 or phosphotyrosine-binding (PTB) domains. To determine how many and
which tyrosines are required to enable EGF receptor-mediated
signaling, we generated a series of EGF receptors that contained
only one tyrosine in their C-terminal tail. Assays of the signaling
capabilities of these single-Tyr EGF receptors indicated that
they can activate a range of downstream signaling pathways,
including MAP kinase and Akt. The ability of the single-Tyr receptors to signal correlated with their ability to bind Gab1 (Grb2-associated binding protein 1). However, Tyr-992 appeared to be almost
uniquely required to observe activation of phospholipase C␥.
These results demonstrate that multiply phosphorylated receptors are not required to support most EGF-stimulated signaling
but identify Tyr-992 and its binding partners as a unique node
within the network. We also studied the binding of the isolated
SH2 domain of Grb2 (growth factor receptor-bound protein 2)
and the isolated PTB domain of Shc (SHC adaptor protein) to
the EGF receptor. Although these adapter proteins bound readily to wild-type EGF receptor, they bound poorly to the singleTyr EGF receptors, even those that bound full-length Grb2 and
Shc well. This suggests that in addition to pTyr-directed associations, secondary interactions between the tail and regions of
the adapter proteins outside of the SH2/PTB domains are
important for stabilizing the binding of Grb2 and Shc to the
single-Tyr EGF receptors.

Signaling by single-tyrosine EGF receptors
receptors correlated with their ability to bind Gab1, identifying this as a key node in the EGF receptor signaling network. These studies demonstrate the robust nature of the
network and focus attention on the role of Tyr-992 and Gab1
in EGF receptor-mediated signaling. They also demonstrate
that multiply phosphorylated EGF receptors are not
required to support many of the downstream signaling
events.

Results
Signaling via EGF receptors with a single tyrosine residue in
their C-terminal tail

Figure 1. Expression and cell surface localization of the “only” EGF receptors. A, Western blot of cell lysates run on a blue native gel. Cells expressing
wild-type or one of the single-Tyr EGF receptors were lysed in RIPA buffer
containing 750 mM ⑀-amino-caproic acid. Lysates were run on a blue native
gel, and EGF receptors were visualized using cetuximab. B, cells stably transfected with each of the single-Tyr receptors were treated with increasing
doses of doxycycline and subjected to 125I-cetuximab binding. 125I-Cetuximab was used rather than 125I-EGF to avoid variations in binding because of
alterations in EGF affinity in the different single-Tyr EGF receptors. Increasing
concentrations of doxycycline are denoted by increasing color from white to
gray to black of the bars. The concentrations of doxycycline used ranged from
25 to 1000 ng for the different lines. C, parental (untransfected) CHO cells
were subjected to 125I-cetuximab binding as in B and are shown in comparison to 125I-cetuximab binding to cells transfected with wild-type EGF receptors. D, anti-ErbB3 or anti-ErbB4 Western blots of parental CHO cells or CHO
cells transfected with ErbB3 (left panel) or ErbB4 (right panel).

these other ErbB receptors. CHO cells do express a minimal
number of ErbB2 (⬃5000 receptors/cell). To prevent signaling
caused by dimerization of the mutant EGF receptors with the
low levels of endogenous ErbB2, all experiments were carried
out in the presence of 5 g/ml pertuzumab, which blocks the
dimerization of ErbB2 with the EGF receptor (20, 21).
To determine whether the single-Tyr EGF receptors retained
their ability to dimerize in response to EGF, membranes were
prepared from cells expressing each of the single-Tyr EGF
receptors as well as cells expressing the Y9F-EGF receptor,
which lacks all nine tyrosines in its C-terminal tail. Membranes
were treated with or without EGF in vitro. The EGF receptors
J. Biol. Chem. (2017) 292(50) 20744 –20755
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SH2 and PTB domain-containing proteins bind to phosphotyrosine residues in the context of a linear recognition motif. To
determine which of the nine tyrosines in the C-terminal tail of
the EGF receptor were principally responsible for mediating
the activation of specific downstream signaling pathways, we
generated a set of nine different EGF receptors in which all but
one of the nine tyrosines were replaced with phenylalanine.
This left only a single tyrosine residue available for phosphorylation and protein binding. We refer to these receptors as the
single-Tyr series of EGF receptors and denote the receptors as,
for example, the Y974-only EGF receptor, which is a receptor
with only Tyr-974 in its C-terminal tail.
Nine stable CHO cell lines, each expressing one of the singleTyr EGF receptors from a tet-inducible promoter, were generated. Fig. 1 shows a Western blot of a gel that was run on cells
expressing the wild-type EGF receptor or each of the single-Tyr
receptors. For this gel, the cells were solubilized in RIPA buffer
but run on a blue native gel. This allowed us to blot with the
monoclonal antibody, cetuximab, which recognizes an epitope
on the extracellular domain of the receptor (19). We found that
with the exception of the Y1068-only EGF receptor, our standard anti-EGF receptor antibody, which recognizes an epitope
around Tyr-1068, did not recognize the single-Tyr EGF receptors. Apparently, Tyr-1068 is a major part of the epitope for this
antibody, and phenylalanine is a poor substitute
As can be seen in Fig. 1A, all nine of the single-Tyr EGF
receptors were expressed in CHO cells. All of the receptors ran
at roughly the same position as the wild-type EGF receptor,
suggesting a similar overall structure and level of glycosylation.
Each cell line was stimulated with several increasing concentrations of doxycycline to induce increased levels of receptor
expression. Subsequently, intact cells were subjected to 125Icetuximab binding to determine whether the single-Tyr receptors were transported to the cell surface. As shown in Fig. 1B,
increasing concentrations of doxycycline led to increasing levels of 125I-cetuximab bound in all cell lines. This indicates that
the single-Tyr receptors are expressed and present on the cell
surface. Although expression levels varied among cell lines, it
was possible to identify concentrations of doxycycline that
yielded similar levels of expression of each single-Tyr receptor.
The parental CHO cells do not express any EGF receptors as
judged by the absence of 125I-cetuximab binding in these cells
(Fig. 1C). Nor do they express ErbB3 or ErbB4 as indicated by
Western blots (Fig. 1D). Thus, any signaling in cells expressing
the single-Tyr EGF receptors cannot be due to interaction with

Signaling by single-tyrosine EGF receptors

were then solubilized with dodecylmaltoside, run on a blue
native gel, and blotted with cetuximab. As shown in Fig. 2A,
addition of EGF to membranes containing the wild-type EGF
receptor led to a shift of the receptor band from a fast moving
monomeric species to a slow moving dimeric species. All of the
single-Tyr EGF receptors, as well as the Y9F-EGF receptor, also
showed this EGF-dependent shift from fast moving monomer
to slow moving dimer. Interestingly, the Y1045-only, Y1114only, and Y9F-EGF receptor monomers ran slightly faster than
the monomer species of the other receptors. Because the receptors all ran at a similar position when solubilized in a denaturing
buffer (Fig. 1A), this difference is likely due to conformational
differences in the tails of these receptors.
In addition to inducing dimerization of all the single-Tyr
EGF receptors, EGF also induced the activation of their tyrosine
kinase activity. For the experiment shown in Fig. 2B, membranes from cells expressing each of the single tyrosine EGF
receptors or the Y9F receptor were incubated with the exoge-
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nous peptide substrate Arg-Arg-Src and [␥-32P]ATP in the
absence or presence of EGF (22). The incorporation of 32P into
the peptide was then measured, and the EGF-stimulated activity is shown in Fig. 2B. All of the single-Tyr receptors, as well as
the Y9F-EGF receptor, exhibited EGF-stimulated tyrosine
kinase activity. Most showed activity in a range that was similar
to that seen for the wild-type EGF receptor. However, the Y974only, Y1148-only, and especially the Y992-only EGF receptors
all showed peptide kinase activity that was significantly higher
than that of the wild-type EGF receptor. By contrast, the Y1045only and Y1101-only EGF receptors exhibited peptide kinase
activity that was approximately half that seen for the wild-type
receptor. These data indicate that the single tyrosine EGF
receptors are expressed on the cell surface, bind EGF, and
dimerize in response to ligand binding. In addition, they all
retain EGF-stimulated tyrosine kinase activity.
To examine signaling by the single-Tyr EGF receptors, cells
expressing each of the receptors were stimulated with EGF and
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Figure 2. EGF-stimulated dimerization and kinase activity of the single-Tyr EGF receptors. A, cells expressing wild-type or each of the single-Tyr EGF
receptors or EGF receptors lacking all nine tyrosines (Y9F) were treated without or with 100 nM EGF and lysed in blue native gel sample buffer containing 0.5%
dodecylmaltoside. Samples were run on blue native gels and subjected to Western blotting with cetuximab. D, dimer; M, monomer. B, membranes were
prepared from cells expressing wild-type or each of the single-Tyr EGF receptors or EGF receptors lacking all nine tyrosines. Membranes were incubated
without or with EGF in the presence of [␥-32P]ATP and the Arg-Arg-Src substrate peptide for 15 min, and the EGF-stimulated incorporation of 32P into the
peptide was quantitated as described under “Experimental procedures.” Assays were performed in triplicate. The graph shows the individual replicates plus
the mean and standard deviation. The shaded bar represents the range of activity observed with membranes from cells expressing wild-type EGF receptors.

Signaling by single-tyrosine EGF receptors

lysates analyzed by SDS-polyacrylamide gel electrophoresis and
Western blotting (Fig. 3). The behavior of the single-Tyr receptors was compared with that of the Y9F-EGF receptor, which
would not be expected to signal because it lacks all nine
tyrosines in its tail (far-right panels of Fig. 3). Receptor levels
were determined based on 125I-cetuximab binding and are
shown in the row marked Binding at the top of the Western
blots. Binding for the single-Tyr receptors was normalized to
that seen for the wild-type EGF receptor.
We first examined the ability of the single-Tyr EGF receptors
to undergo autophosphorylation. Because these receptors have
just one tyrosine as opposed to the nine tyrosines found in the
wild-type receptor, the mutant receptors would be expected to
be phosphorylated at only a fraction of the level of the wild-type
receptor. Therefore, for the anti-phosphotyrosine blots, the
wild-type receptor was loaded at one-third of the standard load
to allow easier comparison with the more weakly phosphorylated single-Tyr receptors. As can be seen in the top panel of Fig.
3, the Y974-only, Y992-only, Y1114-only, and Y1148-only EGF
receptors were detectably phosphorylated. The apparent lack
of phosphorylation of the other single-Tyr receptors appears to
be due to the failure of the PY20 antibody to recognize the
individual phosphotyrosines because EGF-stimulated phosphorylation of the Y1068-only and Y1173-only receptors was
readily detected using phosphosite-specific antibodies (supplemental Fig. S1). In addition, the PY20 antibody was able to
detect phosphorylation of the Y1101-only EGF receptor if
twice as much lysate was loaded on the SDS gel (supplemental Fig. S1). Thus, these anti-phosphotyrosine Western blots

Binding of signaling proteins to the “only” EGF receptors
We have previously used luciferase fragment complementation imaging to visualize the association of multiple downstream signaling proteins with wild-type EGF receptors in
response to different EGF receptor agonists (23). We used this
luciferase complementation system to determine how the presence of a single tyrosine residue in the C-terminal tail of the
EGF receptor affected its ability to bind Shc, Grb2, Gab1, PI3KRI, and Shp2. To do this, the single-Tyr EGF receptors were
C-terminally fused to the N-terminal fragment of firefly luciferase (NLuc). The receptors were transiently transfected into
CHO cells stably expressing Shc, Grb2, Gab1, PI3K-RI, or Shp2
J. Biol. Chem. (2017) 292(50) 20744 –20755
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Figure 3. Signaling by the single-Tyr receptors. Cells stably expressing
wild-type or one of the single-Tyr EGF receptors were treated with 10 nM EGF
for 1, 2, or 5 min at 37 °C as indicated. RIPA lysates were prepared and separated by SDS-PAGE. For the anti-phosphotyrosine blots, the protein load for
the wild-type receptor was one-third that of the single-Tyr receptors. For all
other blots, equal protein was loaded for the wild-type and the single-Tyr
receptors. The values at the top of the Western blots in the line labeled Binding
represent the binding of 125I-cetuximab to each cell line in that experiment,
normalized to that observed for cells expressing the wild-type EGF receptor.

cannot be used to determine whether, and how extensively,
each of the different single-Tyr EGF receptors are phosphorylated, but they do indicate that the receptors are autophosphorylated. As expected, the Y9F receptor was not detectably phosphorylated.
To determine the extent to which these single-Tyr EGF
receptors could mediate cell signaling, we assessed the ability of
EGF to stimulate the activity of several downstream signaling
pathways. Eight of the nine single-Tyr receptors, including
those carrying the rarely phosphorylated Tyr-1101 and Tyr1114, supported activation of MAP kinase (second and third
panels from the top in Fig. 3). Only the Y1045-only EGF receptor and the Y9F-EGF receptors failed to stimulate the activity of
MAP kinase. For many of the single-Tyr EGF receptors, the
level of MAP kinase activation was greater in cells expressing
the mutant receptors than in cells expressing the wild-type
receptor. This may be due to the absence of normal feedback
inhibitory mechanisms in these receptors giving rise to an
unopposed stimulatory signal.
A similar pattern of activation was seen for the EGF-stimulated phosphorylation of Shc, Akt, Gab1, and Stat3. All of the
single-Tyr EGF receptors, with the exception of the Y1045-only
receptor, supported these downstream signaling responses.
Thus, despite the presence of just a single tyrosine residue,
these receptors were remarkably catholic in their ability to
engage downstream signaling molecules. The Y9F-EGF receptor was completely inactive in these assays, indicating that
tyrosines in other parts of the EGF receptor structure were not
able to substitute for any of the tyrosines in the C-terminal tail.
It also suggests that the single-Tyr EGF receptors are not signaling because they have dimerized with another receptor. If
they were, the Y9F-EGF receptor that is kinase-active and capable of dimerizing would have been able to elicit some downstream response, but it did not.
A strikingly different pattern was observed for the phosphorylation of phospholipase C␥. In this case, the Y992-only EGF
receptor robustly stimulated this signaling event to levels significantly higher than what was observed for the wild-type EGF
receptor. In addition, the Y1068-only EGF receptor supported
weak activation of phospholipase C␥. These data indicate that
although some signaling events, such as Gab1 phosphorylation,
are readily supported by most of the single-Tyr EGF receptors,
other pathways, like activation of phospholipase C␥, have a much
more specific requirement for the phosphorylated tyrosine.

Signaling by single-tyrosine EGF receptors

C-terminally fused to the C-terminal fragment of firefly luciferase (C-Luc).
Fig. 4A shows the ability of wild-type and the single-Tyr EGF
receptors to bind p52Shc. The Y1148-only EGF receptor exhibited the highest level of binding to Shc of any of the single-Tyr
receptors. This is consistent with the fact that Y1148 lies within
an NPXY consensus sequence for the binding of the Shc PTB
domain (18). The Y1114-only and the Y1173-only EGF receptors bound Shc about half as well as the wild-type EGF receptor.
The Y1086-only EGF receptor also exhibited modest binding of
Shc. Tyr-1086 and Tyr-1114 both lie within an NPXY consensus sequence that would enable them to bind to the Shc PTB
domain, possibly explaining their strong showing in this assay.
All other members of the single-Tyr series of receptors,
including Y974-only, Y992-only, Y1045-only, Y1068-only, and
Y1101-only, failed to bind Shc, even though most of these
receptors clearly phosphorylated Shc (Fig. 3). Because the
proximal tyrosines in the EGF receptor tail (Tyr-974, Tyr992, Tyr-1045, and Tyr-1068) are not in a consensus
sequence for the direct binding of the Shc PTB domain, these
data suggest that Shc is binding indirectly to these sites to
become phosphorylated. Steric issues may prevent complementation of the luciferase fragments. As expected, the Y9FEGF receptor failed to bind Shc.
Grb2 exhibited a somewhat different pattern of binding to
the single-Tyr EGF receptors (Fig. 4B). Like Shc, Grb2 bound to
the Y1148-only EGF receptor at essentially wild-type levels and
bound about half as well as wild type to Y1173-only EGF receptor. Because neither of these sites are known to bind Grb2
directly, it is likely that the assay is detecting Grb2 binding to
Shc, which was bound to the EGF receptor and phosphorylated.

20748 J. Biol. Chem. (2017) 292(50) 20744 –20755

Grb2 also bound well to the Y1068-only EGF receptor, the
Y1114-only EGF receptor, and also fairly well to the Y1101-only
EGF receptor. Both Tyr-1068 and Tyr-1114 lie within a canonical binding consensus sequence (YXNX) (24) for the Grb2
SH2 domain, and Tyr-1068 has been shown to bind Grb2 (25,
26). Thus, Grb2 is likely binding directly to these two receptors. The sequence surrounding Tyr-1101 (pYQDPH) does
not fit the consensus sequence for the binding of the Grb2
SH2 domain, so it is difficult to explain why Grb2 is binding
to this receptor. It is possible that another adapter protein
binds to this tyrosine and, after phosphorylation, provides a
site for Grb2 binding. We could not detect Grb2 binding to
the proximal tyrosines (Tyr-974, Tyr-992, and Tyr-1045).
Grb2 also failed to bind to the Y9F-EGF receptor, indicating
the need for at least one tyrosine for the binding of this
adapter protein to the EGF receptor.
Gab1 is a major scaffolding protein recruited to the EGF
receptor via Grb2 (27). Because of this relationship, we anticipated that the ability of Gab1 to associate with the EGF receptor
would parallel that of Grb2. Indeed, Gab1 bound well to the
Y1148-only EGF receptor and to the other single-Tyr receptors
to which Grb2 bound, including Y1068-only, Y1086-only,
Y1101-only, Y1114-only, and Y1173-only (Fig. 4C). However,
Gab1 also showed significant binding to single-Tyr receptors
carrying proximal tyrosines-the Y974-only and Y992-only EGF
receptors. These data are consistent with the ability of all of
these single-Tyr receptors to phosphorylate Gab1 (Fig. 3). Like
Shc and Grb2, Gab1 failed to bind to the Y9F-EGF receptor,
demonstrating that its association with the EGF receptor was
dependent upon the presence of at least one phosphotyrosine.
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Figure 4. Binding of signaling proteins to the single-Tyr receptors. Cells stably expressing one of five different signaling proteins fused to CLuc were
transiently transfected with cDNA encoding the wild-type EGF receptor or one of the single-Tyr EGF receptors C-terminally fused to NLuc. The concentration
of EGF that yielded optimal complementation of the EGF receptor with that particular protein (23) was added, and light production in the presence of luciferin
was measured at 30-s intervals for 25 min. A, p52 Shc. B, Grb2. C, Gab1. D, PI3K-RI. E, Shp2.

Signaling by single-tyrosine EGF receptors

Gab1 contains a PH domain that could recruit the protein to
the plasma membrane upon stimulation with EGF, thereby promoting the recruitment Gab1 to the EGF receptor (28). To
determine the extent to which its PH domain contributes to the
recruitment of Gab1 to the EGF receptor, we assessed the effect
of wortmannin on the binding of Gab1 to wild-type EGF receptors, as well as to the single-Tyr series of receptors. Wortmannin is an inhibitor of the PI 3-kinase (29) that generates the PI
3,4,5-P3, through which the Gab1 PH domain is recruited to the
membrane (30). As shown in Fig. 5, pretreatment of cells with
wortmannin did not affect the ability of Gab1 to bind to the
wild-type EGF receptor or the Y1148 only-EGF receptor. However, wortmannin treatment slowed the kinetics of Gab1 association with the other single-Tyr EGF receptors and, in some
cases, also reduced the extent of binding. This suggests that
under non-optimal conditions, the PH domain-dependent
localization of Gab1 to the membrane contributes to the association of Gab1 with the EGF receptor.
PI3K-RI can be recruited to the EGF receptor signaling complex by binding to the YMXM motifs present in Gab1 (24), and
like Gab1, PI3K-RI did bind to the Y1148-only EGF receptor

(Fig. 4D). However, unlike Gab1, PI3K-RI did not associate with
any of the other single-Tyr EGF receptors. Given the observation that all but the Y1045-only EGF receptors supported Akt
activation (Fig. 3) and hence likely mediated activation of the PI
3-kinase, it is possible that the failure of PI3K-RI to show significant complementation with the other single-Tyr receptors
is due to steric issues.
Shp2 can also be recruited to the EGF receptor through Gab1
(31). The data in Fig. 4E demonstrate that Shp2 was recruited
reasonably well to the Y1148-only and Y1114-only EGF receptors. The other single-Tyr receptors showed substantially less
Shp2 binding than these two single-Tyr receptors.
Given the observation that Tyr-1148 appeared to be capable
of mediating the association of all five signaling proteins with
the EGF receptor, we wondered whether the removal of this, or
any other single tyrosine, would substantially affect the ability
of these proteins to bind to the EGF receptor. We therefore
generated a set of EGF receptors in which only one of the nine
tyrosines in the tail was mutated to a phenylalanine. We refer to
these as the “Y-to-F” series and denote the specific mutation as,
for example, Y1148F-EGF receptor. The Y-to-F EGF receptors
J. Biol. Chem. (2017) 292(50) 20744 –20755
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Figure 5. Effect of wortmannin on the binding of Gab1 to the single-Tyr EGF receptors. Cells stably expressing Gab1 C-terminally fused to CLuc were
transiently transfected with cDNA encoding wild-type or one of the single-Tyr EGF receptors fused to NLuc. The cells were treated without or with 100 nM
wortmannin for 40 min at 37 °C and then stimulated with 10 nM EGF and assayed for light production in the presence of luciferin. Open circles in each panel
denote assays in the absence of wortmannin, whereas closed circles represent data from assays done in the presence of wortmannin.

Signaling by single-tyrosine EGF receptors

were C-terminally fused to NLuc and transiently transfected
into CHO cells expressing Shc, Grb2, Gab1, PI3K-RI, or Shp2
C-terminally fused to the CLuc.
Substitution of any one tyrosine in the C-terminal tail of the
EGF receptor with phenylalanine (the Y-to-F series) did not
affect the ability of Shc to bind to the EGF receptor (Fig. 6). In
particular, Shc bound normally to the Y1148F- and Y1173FEGF receptors, despite reports that these two tyrosines represent the major Shc binding sites on the EGF receptor (25, 32).
Thus, in the absence of its major binding site, Shc still binds to
the EGF receptor to the same extent and with similar kinetics as
it does to wild-type EGF receptor. Similarly, removal of any
single tyrosine residue did not affect the ability of Grb2, Gab1,
PI3K-RI, or Shp2 to bind to the EGF receptor. Thus, EGF receptor signaling appears to incorporate significant redundancy so
that the system is not substantially affected by the loss of any
one particular tyrosine, even if it represents a major site of phosphorylation and protein binding.
Binding of mutants of Grb2 to the single-Tyr EGF receptors
Grb2 is an adapter protein composed of one SH2 domain and
two SH3 domains (33). The SH2 domain is responsible for
binding phosphotyrosine residues, whereas the SH3 domains
bind polyproline regions in proteins that are then recruited to
the EGF receptor. If the binding of Grb2 to the EGF receptor is
mediated entirely by its SH2 domain, one would predict that the
binding of the isolated Grb2 SH2 domain to the EGF receptor
mutants should recapitulate the binding of full-length Grb2 to
the single-Tyr EGF receptors.
To test this hypothesis, we generated a construct containing
the isolated SH2 domain of Grb2 C-terminally fused to CLuc.

20750 J. Biol. Chem. (2017) 292(50) 20744 –20755

As shown in Fig. 7A, the isolated Grb2 SH2 domain bound well
to the wild-type EGF receptor. However, it failed to bind to any
of the single-Tyr EGF receptors. This was somewhat surprising
because full-length Grb2 bound well to several of the single-Tyr
EGF receptors, including the Y1148-only, Y1068-only, and
Y1173-only EGF receptors (Fig. 4B). This suggested that the
SH3 domains of full-length Grb2 contributed to its ability to
bind to the single-Tyr EGF receptors.
To test this, we first generated a cDNA that encoded the
Grb2 SH2 domain containing an R86H mutation C-terminally
fused with CLuc. The R86H mutation has been reported to
abolish the ability of the SH2 domain to bind to phosphotyrosine residues (34 –37). As shown in Fig. 7A, whereas the Grb2
SH2 domain bound well to the wild-type EGF receptor (filled
black circles), the R86H-Grb2-SH2 domain did not bind at all
(open black circles). These data demonstrate that the R86H
mutation does in fact ablate the phosphotyrosine binding activity of the Grb2 SH2 domain.
We then assessed whether a full-length Grb2 construct
containing the R86H mutation fused to CLuc could bind to
the wild-type EGF receptor or any of the single-Tyr EGF
receptors. As shown in Fig. 7B, only the Y1114-only EGF
receptor supported a significant level of binding of R86HGrb2. The other single-Tyr EGF receptors bound R86HGrb2 very poorly. Thus, neither the isolated SH2 domain nor
the SH3 domains by themselves are able to mediate the efficient binding of Grb2 to the single-Tyr receptors. This suggests that the ability of full-length Grb2 to bind to the singleTyr EGF receptors involves a collaboration of the SH2 and
SH3 domains of Grb2.
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Figure 6. Binding of signaling proteins to the Y-to-F EGF receptor mutants. Cells stably expressing one of five different signaling proteins fused to CLuc
were transiently transfected with cDNA encoding the wild-type EGF receptor or the indicated Y-to-F single point mutation EGF receptors C-terminally fused to
NLuc. The concentration of EGF that yielded optimal complementation of the EGF receptor with that particular signaling protein (23) was added, and light
production in the presence of luciferin was measured for 25 min. A, p52 Shc. B, Grb2. C, Gab1. D, PI3K-RI. E, SHP2.
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Binding of Shc SH2 and PTB domains to the single-Tyr EGF
receptors
Shc contains an N-terminal PTB domain and a C-terminal SH2
domain. Theoretically, either domain is capable of binding to
phosphotyrosine in the appropriate consensus sequence. To
determine whether the association of Shc with the single-Tyr EGF
receptors was mediated through the SH2 or PTB domain of the
protein, we generated two constructs: one containing the Shc-PTB
domain fused to CLuc and one encoding the Shc-SH2 domain
fused to C-Luc. When transiently transfected into cells stably
expressing the wild-type EGF receptor fused to NLuc, the isolated
PTB domain was found to bind nearly as well to the wild-type EGF
receptor as full-length Shc. However, the isolated SH2 domain
failed to associate with the receptor (Fig. 8A). This confirms prior
reports that the PTB domain, but not the SH2 domain, is responsible for the ability of Shc to bind to the EGF receptor (32).
Although the isolated PTB domain bound well to the wildtype EGF receptor, it bound relatively poorly to the single-Tyr
EGF receptors (Fig. 8B). As can be seen in the figure, the Shc
PTB domain showed significant binding only to the Y1148-only
and Y1173-only EGF receptors. For the Y1148-only receptor,
the binding of the Shc PTB domain was substantially less than
the binding of full-length Shc to this receptor (Fig. 4A). Thus, as
was the case for Grb2, the ability of full-length Shc to bind to the

Figure 8. Binding of Shc SH2 and PTB domains to EGF receptors. A, cells
stably expressing wild-type EGF receptor fused to NLuc were transiently
transfected with full-length wild-type Shc (WT Shc), the isolated Shc PTB
domain (Shc PTB), or the isolated Shc SH2 domain (Shc SH2) fused to CLuc.
Cells were stimulated with 1 nM EGF, and light production in the presence of
luciferase measured. B, cells stably expressing the Shc PTB domain fused to
CLuc were transiently transfected with cDNA encoding wild-type EGF receptor or one of the single-Tyr EGF receptors. Cells were stimulated with 1 nM
EGF, and light production in the presence of luciferin was measured.

single-Tyr EGF receptors appears to involve more than simply
the pTyr/PTB domain interaction.

Discussion
In the current paradigm for EGF receptor-mediated signaling, phosphorylation of tyrosine residues in the C-terminal tail
of the receptor provides docking sites for the binding of signaling proteins that contain SH2 or PTB domains. The EGF receptor contains nine tyrosines in its tail, raising the question of
whether all these tyrosines are needed to support EGF receptor-mediated signaling. Here we present data indicating that
EGF receptors with only a single tyrosine in their C-terminal
tail are able to recapitulate a large number of the signaling activities of the EGF receptor.
All of the single-Tyr EGF receptors dimerized in response to
EGF, indicating that the binding and dimerization functions of
the receptor were intact, despite the changes in the C-terminal
tail. All of the receptors also exhibited EGF-stimulated tyrosine
kinase activity as measured by the phosphorylation of an exogenous peptide substrate. We were also able to detect autophosphorylation of all but the Y1045-only and Y1086-only EGF
receptors. The former likely was not phosphorylated because it
did not signal, but the latter did support some signaling, indicating that it must have been autophosphorylated. It appears
that the pan-anti-phosphotyrosine PY20 antibody cannot
detect this phosphorylation. The fact that the PY20 antibody
J. Biol. Chem. (2017) 292(50) 20744 –20755
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Figure 7. Binding of Grb2 mutants to EGF receptors. A, cells stably
expressing the isolated Grb2-SH2 domain or the R86H-Grb2SH2 domain
C-terminally fused to CLuc were transiently transfected with cDNA encoding the wild-type EGF receptor or one of the single-Tyr EGF receptors
fused to NLuc. The cells were stimulated with 10 nM EGF, and light production in the presence of luciferin was measured. B, cells stably expressing
the isolated Grb2 SH2 domain containing the R86H mutation and fused to
CLuc were transiently transfected with cDNA encoding the wild-type EGF
receptor or one of the single-Tyr EGF receptors. Cells were stimulated with
10 nM EGF, and light production in the presence of luciferin was measured.
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formyl-peptide receptor (43). Finally, the amino acid sequence
surrounding Tyr-992 is conserved in all EGF receptors from
insect to human, as well as in vertebrate ErbB2 and ErbB4.
Together, these findings suggest that Tyr-992 may occupy a
special niche in EGF receptor-mediated signaling that has evolutionarily deep roots.
It is perhaps not surprising that the single-Tyr receptors are
able to signal as widely as the wild-type EGF receptor. Studies
have shown that the stoichiometry of phosphorylation of the
EGF receptor is low (44), and a single molecule approach suggested that the receptor is only rarely multiphosphorylated
(45). Thus, in vivo, the typical receptor may contain only a single phosphorylated tyrosine on its tail. The difference for the
single-Tyr receptors is that unlike a population of singly phosphorylated wild-type receptors that would present an ensemble
of all possible phosphosites, the single-Tyr EGF receptors present one specific phosphorylated tyrosine. Thus, any signaling
through these receptors has to proceed utilizing that one
phosphotyrosine.
A noteworthy observation in our study is the ability of Tyr1101 and Tyr-1114 to support downstream signaling. These
two tyrosines are not normally reported to be phosphorylated
in response to EGF, yet they clearly are able to support signaling
when they represent the only tyrosine in the C-terminal tail. It is
possible that in the wild-type EGF receptor, the phosphorylation of other tyrosines is kinetically preferred, and the subsequent binding of signaling proteins to those phosphotyrosines
precludes the phosphorylation of and signaling through Tyr1101 or Tyr-1114. This implies that steric considerations limit
the number of sites that can be phosphorylated on any given
receptor and is consistent with the low stoichiometry of phosphorylation reported for the EGF receptor (10, 44, 45).
We used the luciferase fragment complementation system to
explore the structural features of Grb2 and Shc that enabled
them to bind to the single-Tyr EGF receptors. Grb2 binds to the
EGF receptor via its SH2 domain, and it is generally accepted
that Shc binds to the EGF receptor through its PTB domain
rather than through its SH2 domain (32). Consistent with this
conclusion, the isolated Grb2 SH2 domain and the isolated Shc
PTB domain, both bound well to wild-type EGF receptor,
whereas the Shc SH2 domain did not bind.
Whereas full-length Grb2 bound well to several of the singleTyr EGF receptors, the isolated SH2 domain of Grb2 did not
bind to any of the single-Tyr EGF receptors. This suggests that
regions of Grb2 outside of the SH2 domain contribute to the
ability of full-length Grb2 to bind to the single-Tyr EGF receptors. R86H-Grb2, which has an inactivated SH2 domain, bound
poorly to most of the single-Tyr EGF receptors and not at all to
the Y9F-EGF receptor. Thus, the SH3 domains alone are also
insufficient for stable binding of Grb2 to the single-Tyr EGF
receptors. These observations imply that the combination of an
SH2 domain-mediated interaction and an SH3 domain-dependent interaction enabled the binding of full-length Grb2 to the
single-Tyr EGF receptors. A similar effect may be occurring in
Shc as the full-length protein bound strongly to the Y1148-only
EGF receptor, but the isolated PTB domain bound relatively
poorly to this receptor.
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failed to detect tyrosine phosphorylation in several of the single-Tyr EGF receptors that were later found to be phosphorylated when site-specific antibodies were used is a cautionary
tale. It is clear that use of this pan-anti-phosphotyrosine antibody does not guarantee the detection of all phosphotyrosines
in a sample.
All of the single-Tyr EGF receptors, except the Y1045-only
receptor, were able to support the activation of multiple downstream signaling pathways. Notably, the ability of a receptor to
activate signaling did not correlate with its peptide kinase activity. For example, the Y1173-only EGF receptor exhibited nearly
wild-type levels of peptide kinase activity but showed relatively
weak signaling in all assays. By contrast, the Y1148-only EGF
receptor exhibited peptide kinase activity that was two to three
times higher than the wild-type EGF receptor and yet showed
only wild-type levels of activation of Gab1 and Stat3 and did not
stimulate the activation of phospholipase C␥ at all. Thus, the
observed signaling differences among the single tyrosine receptors must reflect differences in how, or whether, the remaining
tyrosine residue interacts with different signaling proteins.
The ability of the single-Tyr EGF receptors to bind downstream signaling molecules was variable, possibly because of the
steric requirements necessary to obtain complementation of
the two luciferase fragments. However, all of the single tyrosine
receptors, except the Y1045-only receptor, bound Gab1. The
ability of the single-Tyr EGF receptors to bind Gab1 probably
explains why these receptors were all able to activate signaling
pathways such as MAP kinase and Akt.
Tyr-1148 is typically reported to be the major site of tyrosine
phosphorylation on the EGF receptor (10, 11). Consequently,
the observation that the Y992-only EGF receptor mediated
activation of all six downstream pathways examined, whereas
the Y1148-only EGF receptor activated only five of the pathways, was unexpected. Tyr-992 is known to represent the binding site for phospholipase C ␥ (38). This is probably why the
Y992-only EGF receptor was almost unique in its ability to activate phospholipase C␥. This specificity suggests that, unlike the
other signaling pathways, activation of phospholipase C␥ is
highly dependent on the nature or position of the phosphorylated tyrosine and suggests that Tyr-992 plays a unique role in
EGF receptor-mediated signaling.
Data from several studies using different approaches suggest
that Tyr-992 does indeed represent a distinctive site in the EGF
receptor tail. Tyr-992 is proximal to the kinase domain, and
coarse-grain simulations suggest that the available chain length
beyond the kinase domain is not long enough to permit phosphorylation of this residue in trans within an asymmetric kinase
dimer (39). Rather, Koland (39) speculated that Tyr-992 may be
phosphorylated in cis. Consistent with this view, Huang et al.
(40) presented evidence that phosphorylation of Tyr-992 was
most efficient when the EGF receptor could form higher-order
oligomers. In contrast to dimers where only one kinase domain
is activated, a greater fraction of the kinase domains in oligomers are activated, which would allow more phosphorylation in
cis of Tyr-992. The phosphorylation of Tyr-992 is uniquely
increased after irradiation (41) and after cholesterol depletion
(42), and Tyr-992 phosphorylation is selectively stimulated
after treatment of glioblastoma cells with an agonist of the
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Experimental procedures
Materials
EGF was purchased from Biomedical Technologies. Cetuximab and pertuzumab were obtained from the Barnes–Jewish
Hospital pharmacy. 125I-Cetuximab was generated using the
ICl procedure described previously (46). The PY-20 anti-phosphotyrosine antibody was from BD Transduction Laboratories.
The anti-MAP kinase, anti-Shc, and anti-Gab1 antibodies were
from Millipore. The phospho-MAP kinase antibody was from
Promega. The anti-Akt, phospho-Akt, phospho-Gab1, phospholipase C␥, phosphophospholipase C␥, Stat3, and phoshoStat3 Tyr-709 antibodies were from Cell Signaling. The Tyr-239/
240 phospho-Shc antibodies were obtained from Promega.
FetalPlex was from Gemini Bioproducts. Na125I and [␥-32P]ATP
were from PerkinElmer. Wortmannin was purchased from
Sigma–Aldrich. The substrate peptide Arg-Arg-Leu-Ile-Glu-AspAla-Glu-Tyr-Ala-Ala-Arg-Gly was synthesized and purified
in-house.
DNA constructs
The single-Tyr series of EGF receptors was generated
through multiple rounds of site-directed mutagenesis that ultimately substituted a phenylalanine for all but one tyrosine. To
reduce the number of rounds of mutagenesis, the codon encoding Ala-1078 was altered to generate an FseI site while retaining
Ala at that position. This allowed us to mutate the four
tyrosines N-terminal to the FseI site and the five tyrosines
C-terminal to the FseI site independently and then ligate the
appropriate fragments together to obtain the desired single-Tyr
receptor. The Y-to-F series of EGF receptors were generated by

site-directed mutagenesis of the wild-type EGF receptor using
primers that converted a single tyrosine to a phenylalanine. All
constructs were generated in the pBI-Tet vector, which allowed
induction of the mutant receptor with doxycycline. For luciferase complementation experiments, constructs were fused with
the NLuc fragment of firefly luciferase as described previously
(47).
The R86H mutation was introduced into Grb2 by site-directed
mutagenesis. The Grb2-SH2 domain, without or with the R86H
mutation, was generated by introducing a BsiWI site at amino acid
position 153 of Grb2, allowing fusion in-frame with the CLuc fragment of firefly luciferase in the pcDNA 3.1 Zeo vector.
The constructs encoding the PTB and SH2 domains of Shc were
generated by site-directed mutagenesis of wild-type Shc using
primers that flanked the region of deletion. The PTB domain construct retained only those residues N-terminal of Pro-210. The
SH2 construct retained the residues C-terminal of Pro-365.
Cell lines
The stable cell lines constitutively expressing the five signaling proteins fused to CLuc (Shc, Grb2, Gab1, PI3K-RI, and
SHP2) were derived as described previously (23). CHO cells
were transfected with cDNAs encoding each of the nine singleTyr receptors without the luciferase fragment plus the pTK
hygromycin vector (Clontech) for purposes of selection. Stable
clonal lines were selected by growth in 100 g/hygromycin. The
cells were maintained in DMEM with 10% Fetalplex plus 100
g/ml G418 and 100 g/ml hygromycin.
Blue native gel electrophoresis
Blue native gels were run according to the protocol of Wittig
et al. (48). For the experiment in Fig. 1, samples were prepared
by scraping cells from a 35-mm well into 0.3 ml of RIPA buffer
containing 750 mM ⑀-amino-caproic acid to disrupt receptor
oligomers. For the experiment in Fig. 2, membranes were prepared as outlined below and solubilized in sample preparation
buffer (48) containing 0.50% dodecylmaltoside by passing the
material through a 25-gauge needle 10 times. Undissolved
material was pelleted, loading buffer was added, and the supernatant was applied to the gel. Samples were run overnight at
4 °C, and gels were transferred to PVDF. EGF receptors were
visualized by Western blotting with cetuximab.
Phosphorylation of the exogenous peptide substrate
For each cell line, the membranes were prepared from three
D150 tissue culture plates by scraping the cells into 5 ml of 10
mM Tris, pH 7.2, 75 mM NaCl plus protease inhibitor mixture
and lysing with 20 strokes in a Dounce homogenizer. Unbroken
cells and heavy organelles were removed by a low-speed spin,
and purified membranes were recovered by centrifuging the
supernatant at 17,000 rpm for 20 min in an SS34 rotor in an
RC-5B centrifuge. The membranes were resuspended in ⬃150
l 70 mM ␤-glycerophosphate, pH 7.2, 200 mM NaCl. 125I-Cetuximab binding was performed on the membranes, and membrane volume was subsequently adjusted to obtain an equal
number of EGF receptors per 30-l aliquot. Pertuzumab was
added to the membranes at a final concentration of 8.3 g/ml.
J. Biol. Chem. (2017) 292(50) 20744 –20755
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We speculate that in Grb2, the SH2 domain initiates the
interaction of the adapter protein with the tyrosine-phosphorylated EGF receptor but that additional contacts between the
tail and the Grb2 SH3 domains, or its recruited cargo protein,
further stabilize the association of Grb2 with the single-Tyr
EGF receptors. The structural plasticity of the intrinsically disordered C-terminal tail could facilitate the formation of such
secondary interactions, thereby enhancing the affinity and
specificity of the binding proteins for the EGF receptor tail.
In summary, we have shown that EGF receptors bearing only
a single tyrosine in their C-terminal tail are capable of activating
a broad range of downstream signaling pathways, demonstrating the adaptability of the EGF signaling network. However, the
strong dependence of phospholipase C␥ activation on the presence of Tyr-992 suggests that at least some signaling pathways
exhibit strong site specificity and may be regulated differently
than other more generally activatable pathways, like MAP
kinase. The enhanced phosphorylation of Tyr-992 by EGF
receptor oligomers (40) and the strong requirement for Tyr992 for activation of phospholipase C␥ suggest the possibility
that different oligomeric states of the receptor may mediate the
activation of specific downstream responses. This offers a new
opportunity for the design of selective inhibitors of particular
EGF-stimulated signaling pathways. This could also explain the
biased signaling that is apparent in the EGF receptor system
(23) if different EGF receptor agonists induce different levels of
higher-order receptor oligomers.
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Kinase assays contained 30-l membranes, 5 l of 20 mM
Arg-Arg-Src peptide plus 5 l of 250 nM EGF or buffer. Assays
were started by the addition of 10 l of ATP mix containing 250
M [␥-32P]ATP, 60 mM MgCl2, 10 mM MnCl2, 100 mM p-nitrophenol, and 500 M sodium orthovanadate (49). Assays were
incubated for 15 min at 30 °C and stopped by the addition of 50
l of 10% trichloroacetic acid. Precipitated material was pelleted by centrifugation, and 75 l of the supernatant was spotted onto small squares of phosphocellulose paper. The papers
were washed in 75 mM H3PO4 for 30 min with three changes of
buffer. After drying, the papers were counted for 32P in a liquid
scintillation counter.
Receptor autophosphorylation and downstream signaling

125

I-Cetuximab binding

Cell surface EGF receptor levels were assessed by incubating
triplicate wells of a 48-well dish with 120 pM 125I-cetuximab.
The plates were incubated overnight at 4 °C and then washed
three times in phosphate-buffered saline. Cell monolayers were
dissolved in 1 N NaOH, and the solution was counted for 125I.
Nonspecific binding was determined in replicate wells to which
60 nM unlabeled cetuximab had been added.
Luciferase assays
CHO cells stably expressing Shc, Grb2, Gab1, PI3K-RI, or
Shp2 fused to CLuc (23) were plated in 96-well black-walled
dishes, and 24 h later were transiently transfected with cDNA
encoding one of the single-Tyr or Y-to-F EGF receptors or
wild-type EGF receptor each fused to the NLuc. Three different concentrations of wild-type EGF receptor DNA and
two different concentrations of mutant EGF receptor DNA
were transfected in every experiment to allow comparisons
to be made between cells expressing similar amounts of wildtype and mutant EGF receptor. After an additional 24 h of
growth in the presence of the appropriate concentration of
doxycycline, the cells were assayed for luciferase activity in
the absence or presence of EGF. Cell surface EGF receptor
expression levels were assessed by measuring the binding of
125
I-cetuximab in parallel wells.
Luciferase assays were performed in hextuplicate as
described previously (23). The lines through the data were
drawn using an equation that represents the sum of a logistics association equation and an exponential dissociation
equation (23).
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Supplemental Figure 1

Western blotting for autophosphorylation of the Y1101-only, Y1068-only and Y1173 only EGF
receptors. Cells expressing the indicated single-Tyr EGF receptors were treated in the absence or
presence of 10 nM EGF for the indicated time and RIPA lysates prepared. Left panel) A double
load of the lysate from cells expressing the Y1101-only EGF receptor was probed with the antiphosphotyrosine antibody PY20. Middle panel) A standard load of lysate from cells expressing
the Y1068-only EGF receptor was blotted using the site-specific anti-pY1068 antibody. Right
panel) A standard load of lysate from cells express the Y1173-only EGF receptor was blotted
using the site-specific anti-pY1173 antibody.

Epidermal growth factor receptors containing a single tyrosine in their C-terminal
tail bind different effector molecules and are signaling-competent
Kamaldeep Gill, Jennifer L. Macdonald-Obermann and Linda J. Pike
J. Biol. Chem. 2017, 292:20744-20755.
doi: 10.1074/jbc.M117.802553 originally published online October 26, 2017

Access the most updated version of this article at doi: 10.1074/jbc.M117.802553

Click here to choose from all of JBC's e-mail alerts

Supplemental material:
http://www.jbc.org/content/suppl/2017/10/26/M117.802553.DC1
This article cites 49 references, 20 of which can be accessed free at
http://www.jbc.org/content/292/50/20744.full.html#ref-list-1

Downloaded from http://www.jbc.org/ at Washington University on January 5, 2018

Alerts:
• When this article is cited
• When a correction for this article is posted

